Adaptimmune Therapeutics PLC reports results for the quarter ended March 31 - Earnings Summary

Adaptimmune Therapeutics

14/05/2025 10:41

Adaptimmune Therapeutics PLC ADAP.OQ reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -18 cents.  The mean expectation of eight analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -23 cents to -3 cents per share.

Revenue rose 28.3% to $7.29 million from a year ago; analysts expected $6.17 million.

Adaptimmune Therapeutics PLC's reported EPS for the quarter was a loss of 3 cents​.

The company reported a quarterly loss of $47.58 million.

Adaptimmune Therapeutics PLC shares had risen by 26.9% this quarter and lost 53.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 22.2% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "hold."

Wall Street's median 12-month price target for Adaptimmune Therapeutics PLC is $1.50

This summary was machine generated from LSEG data May 14 at 09:41 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.12
-0.03
Beat
Dec. 31 2024
-0.13
-0.24
Missed
Sep. 30 2024
-0.13
-0.01
Beat
Jun. 30 2024
-0.07
0.24
Beat